Enanta Pharmaceuticals to Present Preclinical Data for EDP-721, its Novel Oral Hepatitis B Virus RNA Destabilizer, at the International Liver Congress™ 2021 Sponsored by the European Association for the Study of the Liver
Enantas research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH).
- Enantas research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH).
- Enanta is also conducting research in SARS-CoV-2 (COVID-19) and human metapneumovirus (hMPV).
- Enantas research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie.
- Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir).